Menu
Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. Inari has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by the FDA and CE Mark approved for the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by the FDA and CE Mark approved for the treatment of pulmonary embolism and clot in transit in the right atrium.
IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the publication of its 2023 Ethos and Sustainability Report. The report highlights Inari’s commitment to its ethos and important corresponding environmental, social and governance (ESG) initiatives. The report can be found on Inari’s website here.
Inari Medical, Inc. (NARI) releases its 2023 Ethos and Sustainability Report, showcasing its commitment to ESG initiatives. The report emphasizes the company''s dedication to treating patients with venous and other diseases while prioritizing environmental and social responsibilities.
NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Inari Medical Inc. (“Inari” or the “Company”) (NASDAQ:NARI) for potential violations of the federal securities laws. The firm’s investigation is in connection with Inari’s recent disclosure that the U.S. Department of Justice sent the Company a civil investigative demand concerning an investigation under the federal Anti-Kickback Statute and Civil False Claims Act, related to payments made to healthcare professionals.
https://www.investing.com/news/company-news/inari-medical-hires-new-sales-and-medical-affairs-vps-93CH-3362685
NEW YORK, NY - ( NewMediaWire ) - March 19, 2024 - Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) is investigating claims on behalf of investors of Inari Medical, Inc. (“Inari Medical” or the “Company”) (NASDAQ: NARI). Click here to join the investigation. If you acquired Inari Medical shares and would like to discuss our investigation, please click here or contact us by emailing pmayer@kaplanfox.com or by calling (646) 315-9003. On February 28, 2024, after the market close, Inari Medical announced fourth quarter and full-year 2023 financial results and disclosed receipt of a civil investigative demand in December 2023 from the U.S. Department of Justice (“DOJ”) “requesting information primarily related to meals and consulting service payments provided to healthcare professionals.” In the Company’s Annual Report filed the next day with the SEC, Inari Medical indicated that that the DOJ request was in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act.
NEW YORK, NY - ( NewMediaWire ) - March 18, 2024 - Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) is investigating claims on behalf of investors of Inari Medical, Inc. (“Inari Medical” or the “Company”) (NASDAQ: NARI). Click here to join the investigation. If you acquired Inari Medical shares and would like to discuss our investigation, please click here or contact us by emailing pmayer@kaplanfox.com or by calling (646) 315-9003. On February 28, 2024, after the market close, Inari Medical announced fourth quarter and full-year 2023 financial results and disclosed receipt of a civil investigative demand in December 2023 from the U.S. Department of Justice (“DOJ”) “requesting information primarily related to meals and consulting service payments provided to healthcare professionals.” In the Company’s Annual Report filed the next day with the SEC, Inari Medical indicated that that the DOJ request was in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act.
https://www.investing.com/news/stock-market-news/inari-medical-cfo-sells-shares-worth-over-250k-93CH-3338739
RADNOR, Pa., March 12, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Inari Medical, Inc. (NASDAQ: NARI) ("Inari Medical"). On February 28,…
